Menu
Log in

Members

 

The content of this section is accessible to members only.

Please note that only full members of SIOPEN have access to SIOPEN presentations/data online.

If you wish to become a SIOPEN member, please enter the page "JOIN US"


Click post title to see full content

  • 28 Apr 2025 10:41 AM | Anonymous member (Administrator)

    Lucas Moreno, Steven G. Dubois, Nicholas Bird, Leona Knox, Donna Ludwinski, Andrew D. J. Pearson, Maja Beck-Popovic, Rochelle Bagatell

    A 2035 Clinical Research Vision and Roadmap for High-Risk Neuroblastoma

    This article outlines a forward-thinking strategy for high-risk neuroblastoma. Although some progress has been made—particularly with the introduction of immunotherapy—the overall survival rates for these patients remain disappointingly low, and those who survive often endure serious long-term consequences.

    The authors present a global, coordinated plan to improve outcomes by 2035. They examine why progress has been so slow, identifying critical challenges such as delayed clinical trial timelines, limited access to new treatments, and a lack of incentives for pharmaceutical companies to invest in pediatric drug development. They emphasise not only the scientific innovations needed but also the systemic, policy, and ethical shifts required to truly transform care.

    The paper proposes a roadmap that calls for:

    • Better and wider global collaboration

    • Smarter and faster trial and adaptive trial designs.

    • Integration of novel biomarkers

    • More regulatory flexibility

    • Expanded patient access worldwide

    Ultimately, this vision is not just about improving survival rates—it’s about changing how we approach pediatric cancer research and treatment as a whole: with urgency, equity, and humanity.

    pubmed logo

    ____________________

    Who we serve: Researchers | Dimensions

    PDF full text available for SIOPEN members


Content available to all SIOPEN members:



Content available for specific SIOPEN members:


This page is available only for Leadership group (President, Vice-presidents, Manager)


This page is available only for Executive committee members


This page is available only for Board members

This page contain different pages for each Specialty Committee that is restricted to its members.

Chair and co-chairs contact list is available to all SIOPEN members.

The purpose of the Association is to perform and facilitate clinical, translational and basic research for children and adolescents with neuroblastoma in European countries as well as worldwide in order to improve the outcome of these patients.

VAT no. ATU71323212

SIOPEN Verein zur Förderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code. Registration number ZVR 396592912.



Powered by Wild Apricot Membership Software